Insider · CIK 0001781026
Diane L. Parks
director
Files at SNGX (SOLIGENIX, INC.), KURA (Kura Oncology, Inc.), CELU (Celularity Inc). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +78,947 | $0.00 | $0 | 78,947 | 24 d ago |
| Jan 12, 2026 | CELU Celularity Inc | AGrant or award Class A Common Stock | +30,000 | $0.00 | $0 | 520,021 | Jan 15, 2026 |
| Jan 12, 2026 | CELU Celularity Inc | AGrant or award Class A Common Stock | +30,000 | $0.00 | $0 | 520,021 | Jan 14, 2026 |
| Dec 29, 2025 | CELU Celularity Inc | AGrant or award Class A Common Stock | +125,000 | $0.00 | $0 | 490,021 | Dec 30, 2025 |
| Dec 29, 2025 | CELU Celularity Inc | AGrant or award Stock Optionsderivative | +156,250 | $0.00 | $0 | 518,774 | Dec 30, 2025 |
| Dec 19, 2025 | CELU Celularity Inc | AGrant or award Class A Common Stock | +67,416 | $0.00 | $0 | 365,021 | Dec 22, 2025 |
| Nov 19, 2025 | CELU Celularity Inc | AGrant or award Class A Common Stock | +61,539 | $0.00 | $0 | 365,021 | Nov 21, 2025 |
| Jun 20, 2025 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +17,647 | $0.00 | $0 | 17,647 | Jun 20, 2025 |
| Jun 5, 2025 | KURA Kura Oncology, Inc. | AGrant or award Option to purchase common stockderivative | +28,500 | $0.00 | $0 | 28,500 | Jun 6, 2025 |
| Dec 19, 2024 | CELU Celularity Inc | AGrant or award Class A Common Stock | +67,416 | $0.00 | $0 | 303,482 | Jan 7, 2025 |
| Dec 19, 2024 | CELU Celularity Inc | AGrant or award Stock Option (Right to Buy)derivative | +84,746 | $0.00 | $0 | 362,524 | Jan 7, 2025 |
| Dec 12, 2024 | SNGX SOLIGENIX, INC. | AGrant or award Stock Option (Right to Buy)derivative | +8,646 | $0.00 | $0 | 8,646 | Dec 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.